| Identification | Back Directory | [Name]
Pyronaridine | [CAS]
74847-35-1 | [Synonyms]
Pyronaridine
Malaridine phosphate
4-(2-Methoxy-6-chloro-1,10-diazaanthracene-9-ylamino)-2,6-bis(pyrrolizinomethyl)phenol
4-(7-chloro-2-Methoxybenzo[b][1,5]naphthyridin-10-ylaMino)-2,6-bis(pyrrolidin-1-ylMethyl)phenol
4-[(7-Chloro-2-methoxybenzo[b]-1,5-naphthyridin-10-yl)amino]-2,6-bis(1-pyrrolidinylmethyl)phenol
4-[(7-CHLORO-2-METHOXY-1,5-DIHYDROBENZO[B][1,5]NAPHTHYRIDIN-10-YL)IMINO]-2,6-BIS(PYRROLIDIN-1-YLMETHYL)CYCLOHEXA-2,5-DIEN-1-ONE | [EINECS(EC#)]
1533716-785-6 | [Molecular Formula]
C29H32ClN5O2 | [MOL File]
74847-35-1.mol | [Molecular Weight]
518.05 |
| Chemical Properties | Back Directory | [Appearance]
solid | [Boiling point ]
621.3±55.0 °C(Predicted) | [density ]
1.356±0.06 g/cm3 (20℃ 760 Torr) | [refractive index ]
1.5650 (estimate) | [pka]
8.20±0.50(Predicted) | [Stability:]
Incompatible with strong oxidizing agents. | [CAS DataBase Reference]
74847-35-1 |
| Hazard Information | Back Directory | [Chemical Properties]
solid | [Definition]
ChEBI:Pyronaridine is an aminoquinoline. | [Antimicrobial activity]
Pyronaridine is active against the asexual erythrocytic stage of
P. falciparum with little or no activity against gametocytes or the
hepatic stage. In-vitro blood schizonticide activities are in the
range of 0.001–0.03 mg/L, showing a moderate correlation to
chloroquine resistance. However, this correlation varies between
studies and does not seem to be clinically significant. It is also
active against P. vivax, P. ovale and P. malariae. Antagonistic
interactions with artemisinins were reported in vitro, but synergy
with artesunate has been observed in rodent models. | [Acquired resistance]
Decreasing in-vitro sensitivity has been observed in China. | [Pharmaceutical Applications]
An aza-aminoacridine formulated for oral use. A Mannichbase
derivative of mepacrine. | [Pharmacokinetics]
Peak plasma concentrations are reached after 3–14 h depending
upon the formulation; there is also considerable interindividual
variation. Elimination half-lives of 63–190 h have
been reported, again dependent upon the formulation. | [Clinical Use]
Treatment of uncomplicated P. falciparum and P. vivax malaria
A fixed-dose combination with artesunate (Pyramax) is being
developed for uncomplicated P. falciparum and P. vivax malaria. | [Side effects]
It is well tolerated and no outstanding toxic effects have been
reported. |
|
| Company Name: |
Ralington Pharma
|
| Tel: |
+91-7948911722 +91-9687771722 |
| Website: |
www.ralingtonpharma.com |
|